美国 · SEC FORM 4
Enliven Therapeutics, Inc.
ELVN · Nasdaq · CIK 0001672619 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
55 同一窗口内观察到的 Form 4 交易行
42 sales · 13 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2023-02-23 · COMMODORE CAPITAL LP · $13.7K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Collins Helen LouiseCHIEF MEDICAL OFFICER
○▼○▼○▼○▼○▼
Hohl BenjaminCHIEF FINANCIAL OFFICER
○▼○▼▼○▼
Derynck Mika KDirector
○▼
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCTenPercentOwner
▼▼
Kunkel Lori AnneDirector
▼▼
Garland J. ScottDirector
○▼
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-02-23 · COMMODORE CAPITAL LP.
近期 Form 4 活动
0买入
75卖出
25其他 Form 4 交易行
40SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出42 sale line(s) · 仅供背景
其他13 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,356,282
- 上期报告
- 8,620,503
- 日均成交量
- 1,887,497
- 回补天数
- 5.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-02-23 | COMMODORE CAPITAL LP | 买入 (P) | Common stock, par value $0.001 per share | 622 | USD 22.07 | USD 13,722 | SEC 申报 ↗ |
| 2023-02-22 | COMMODORE CAPITAL LP | 买入 (P) | Common stock, par value $0.001 per share | 23,565 | USD 5.11 | USD 120,417 | SEC 申报 ↗ |
| 2023-02-21 | COMMODORE CAPITAL LP | 买入 (P) | Common stock, par value $0.001 per share | 8,194 | USD 5.25 | USD 43,018 | SEC 申报 ↗ |
| 2023-01-03 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 629,297 | USD 4.00 | USD 2,517,188 | SEC 申报 ↗ |
| 2022-12-09 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 19,299 | USD 3.93 | USD 75,845 | SEC 申报 ↗ |
| 2022-12-08 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 10,600 | USD 3.75 | USD 39,750 | SEC 申报 ↗ |
| 2022-10-24 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 26,460 | USD 3.91 | USD 103,459 | SEC 申报 ↗ |
| 2022-10-21 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 48,100 | USD 3.92 | USD 188,552 | SEC 申报 ↗ |
| 2022-10-20 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 11,342 | USD 3.95 | USD 44,801 | SEC 申报 ↗ |
| 2022-10-19 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 125,726 | USD 3.89 | USD 489,074 | SEC 申报 ↗ |
| 2022-10-18 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 234,799 | USD 3.76 | USD 882,844 | SEC 申报 ↗ |
| 2022-10-17 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 145,672 | USD 3.36 | USD 489,458 | SEC 申报 ↗ |
| 2022-06-16 | Leonard Braden Michael | 买入 (P) | Common Stock | 83,199 | USD 1.11 | USD 92,351 | SEC 申报 ↗ |
| 2022-06-06 | Leonard Braden Michael | 买入 (P) | Common Stock | 2,630 | USD 1.16 | USD 3,051 | SEC 申报 ↗ |
| 2022-06-03 | Leonard Braden Michael | 买入 (P) | Common Stock | 30,800 | USD 1.14 | USD 35,112 | SEC 申报 ↗ |
Form 4 申报证据
100 transaction lines in the latest 365-day window; 564 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Garland J. Scott | 卖出 (S) | Common Stock | 13,000 | USD 46.67 | USD 606,719 | SEC 申报 ↗ |
| 2026-10-01 | Garland J. Scott | 期权行权／转换 (M) | Common Stock | 13,000 | USD 15.47 | USD 201,110 | SEC 申报 ↗ |
| 2026-09-17 | Hohl Benjamin | 卖出 (S) | Common Stock | 6,018 | USD 50.35 | USD 303,016 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Garland J. Scott | 卖出 (S) | Common Stock | 13,000 | USD 46.67 | USD 606,719 | SEC 申报 ↗ |
| 2026-10-01 | Garland J. Scott | 期权行权／转换 (M) | Common Stock | 13,000 | USD 15.47 | USD 201,110 | SEC 申报 ↗ |
| 2026-09-17 | Hohl Benjamin | 卖出 (S) | Common Stock | 6,018 | USD 50.35 | USD 303,016 | SEC 申报 ↗ |
| 2026-09-17 | Hohl Benjamin | 期权行权／转换 (M) | Common Stock | 3,982 | USD 14.85 | USD 59,133 | SEC 申报 ↗ |
| 2026-09-17 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 50.35 | USD 251,752 | SEC 申报 ↗ |
| 2026-09-17 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 5,000 | USD 2.48 | USD 12,400 | SEC 申报 ↗ |
| 2026-08-17 | Hohl Benjamin | 卖出 (S) | Common Stock | 6,018 | USD 58.58 | USD 352,538 | SEC 申报 ↗ |
| 2026-08-17 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 58.59 | USD 292,928 | SEC 申报 ↗ |
| 2026-08-17 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 5,000 | USD 2.48 | USD 12,400 | SEC 申报 ↗ |
| 2026-08-04 | Derynck Mika K | 卖出 (S) | Common Stock | 158,795 | USD 60.21 | USD 9,561,047 | SEC 申报 ↗ |
| 2026-08-04 | Derynck Mika K | 期权行权／转换 (M) | Common Stock | 158,795 | USD 10.84 | USD 1,720,967 | SEC 申报 ↗ |
| 2026-07-17 | Hohl Benjamin | 卖出 (S) | Common Stock | 6,018 | USD 52.64 | USD 316,777 | SEC 申报 ↗ |
| 2026-07-17 | Hohl Benjamin | 期权行权／转换 (M) | Common Stock | 1,072 | USD 2.48 | USD 2,659 | SEC 申报 ↗ |
| 2026-07-17 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 52.67 | USD 263,370 | SEC 申报 ↗ |
| 2026-07-17 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 5,000 | USD 2.48 | USD 12,400 | SEC 申报 ↗ |
| 2026-07-06 | Kunkel Lori Anne | 卖出 (S) | Common Stock | 10,000 | USD 50.49 | USD 504,865 | SEC 申报 ↗ |
| 2026-06-22 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 卖出 (S) | Common Stock | 860,123 | USD 45.36 | USD 39,014,046 | SEC 申报 ↗ |
| 2026-06-17 | Hohl Benjamin | 卖出 (S) | Common Stock | 6,018 | USD 43.80 | USD 263,576 | SEC 申报 ↗ |
| 2026-06-17 | Hohl Benjamin | 期权行权／转换 (M) | Common Stock | 6,018 | USD 2.48 | USD 14,925 | SEC 申报 ↗ |
| 2026-06-17 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 43.80 | USD 219,017 | SEC 申报 ↗ |
| 2026-06-17 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 5,000 | USD 2.48 | USD 12,400 | SEC 申报 ↗ |
| 2026-06-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 卖出 (S) | Common Stock | 281,408 | USD 45.02 | USD 12,668,988 | SEC 申报 ↗ |
| 2026-06-05 | Kunkel Lori Anne | 卖出 (S) | Common Stock | 10,000 | USD 34.54 | USD 345,362 | SEC 申报 ↗ |
| 2026-05-18 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 39.79 | USD 198,962 | SEC 申报 ↗ |
| 2026-05-18 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 5,000 | USD 2.48 | USD 12,400 | SEC 申报 ↗ |
| 2026-04-17 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 47.67 | USD 238,364 | SEC 申报 ↗ |
| 2026-04-17 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 5,000 | USD 2.48 | USD 12,400 | SEC 申报 ↗ |
| 2026-03-25 | Collins Helen Louise | 卖出 (S) | Common Stock | 40,000 | USD 35.10 | USD 1,404,000 | SEC 申报 ↗ |
| 2026-03-25 | Collins Helen Louise | 期权行权／转换 (M) | Common Stock | 40,000 | USD 2.48 | USD 99,200 | SEC 申报 ↗ |
| 2026-03-17 | Collins Helen Louise | 卖出 (S) | Common Stock | 5,000 | USD 27.76 | USD 138,800 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ELVN |
| CIK | 0001672619 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 564 transaction lines from 2020-03-12 to 2026-10-01 44 P purchase lines · 364 S sale lines · 156 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.